WO2003049690A3 - Inhibiteurs de l'integrase du vih - Google Patents

Inhibiteurs de l'integrase du vih Download PDF

Info

Publication number
WO2003049690A3
WO2003049690A3 PCT/US2002/039092 US0239092W WO03049690A3 WO 2003049690 A3 WO2003049690 A3 WO 2003049690A3 US 0239092 W US0239092 W US 0239092W WO 03049690 A3 WO03049690 A3 WO 03049690A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv integrase
integrase inhibitors
formula
tautomer
prodrug
Prior art date
Application number
PCT/US2002/039092
Other languages
English (en)
Other versions
WO2003049690A2 (fr
Inventor
Michael A Walker
Jacques Banville
Roger Remillard
Serge Plamondon
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL16232502A priority Critical patent/IL162325A0/xx
Priority to AU2002366604A priority patent/AU2002366604A1/en
Priority to HU0402675A priority patent/HUP0402675A2/hu
Priority to CA002469592A priority patent/CA2469592C/fr
Priority to JP2003550741A priority patent/JP2005515206A/ja
Priority to NZ533413A priority patent/NZ533413A/en
Priority to KR10-2004-7009018A priority patent/KR20040065251A/ko
Priority to BR0214842-0A priority patent/BR0214842A/pt
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to MXPA04005623A priority patent/MXPA04005623A/es
Priority to EP02804741A priority patent/EP1467695A2/fr
Publication of WO2003049690A2 publication Critical patent/WO2003049690A2/fr
Publication of WO2003049690A3 publication Critical patent/WO2003049690A3/fr
Priority to IS7305A priority patent/IS7305A/is
Priority to HR20040534A priority patent/HRP20040534A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C207/00—Compounds containing nitroso groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C207/00—Compounds containing nitroso groups bound to a carbon skeleton
    • C07C207/04—Compounds containing nitroso groups bound to a carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
    • C07C239/08—Hydroxylamino compounds or their ethers or esters
    • C07C239/20—Hydroxylamino compounds or their ethers or esters having oxygen atoms of hydroxylamino groups etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/63—Carboxylic acid nitriles containing cyano groups and nitrogen atoms further bound to other hetero atoms, other than oxygen atoms of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C255/64—Carboxylic acid nitriles containing cyano groups and nitrogen atoms further bound to other hetero atoms, other than oxygen atoms of nitro or nitroso groups, bound to the same carbon skeleton with the nitrogen atoms further bound to oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention a trait à l'inhibition de l'intégrase du VIH, et au traitement du SIDA ou du para-SIDA par l'administration de composés représentés par la formule (I), ou d'un tautomère desdits composés, ou d'un sel pharmaceutiquement acceptable, d'un solvant ou d'un promédicament desdits composés. R1, R2 et B1 sont tels que définis dans le descriptif de l'invention.
PCT/US2002/039092 2001-12-12 2002-12-06 Inhibiteurs de l'integrase du vih WO2003049690A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
KR10-2004-7009018A KR20040065251A (ko) 2001-12-12 2002-12-06 Ｈｉｖ 인티그레이즈 억제제
HU0402675A HUP0402675A2 (hu) 2001-12-12 2002-12-06 HIV integráz inhibitor hatású hidroxilaminszármazékok, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
CA002469592A CA2469592C (fr) 2001-12-12 2002-12-06 Inhibiteurs de l'integrase du vih
JP2003550741A JP2005515206A (ja) 2001-12-12 2002-12-06 Ｈｉｖインテグラーゼ・インヒビター
NZ533413A NZ533413A (en) 2001-12-12 2002-12-06 HIV integrase inhibitors
IL16232502A IL162325A0 (en) 2001-12-12 2002-12-06 Hiv integrase inhibitor compounds and pharmaceutical compositions containing the same
BR0214842-0A BR0214842A (pt) 2001-12-12 2002-12-06 Inibidores de integrase hiv
AU2002366604A AU2002366604A1 (en) 2001-12-12 2002-12-06 Hiv integrase inhibitors
MXPA04005623A MXPA04005623A (es) 2001-12-12 2002-12-06 Inhibidores de integrasa del virus de inmunodeficiencia humana (vih).
EP02804741A EP1467695A2 (fr) 2001-12-12 2002-12-06 Inhibiteurs de l'integrase du vih
IS7305A IS7305A (is) 2001-12-12 2004-06-10 HIV-integrasa tálmar
HR20040534A HRP20040534A2 (en) 2001-12-12 2004-06-11 Hiv integrase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33967401P 2001-12-12 2001-12-12
US60/339,674 2001-12-12

Publications (2)

Publication Number Publication Date
WO2003049690A2 WO2003049690A2 (fr) 2003-06-19
WO2003049690A3 true WO2003049690A3 (fr) 2004-01-22

Family

ID=23330105

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/039092 WO2003049690A2 (fr) 2001-12-12 2002-12-06 Inhibiteurs de l'integrase du vih

Country Status (24)

Country Link
US (1) US6777440B2 (fr)
EP (1) EP1467695A2 (fr)
JP (1) JP2005515206A (fr)
KR (1) KR20040065251A (fr)
CN (1) CN1617849A (fr)
AR (1) AR037770A1 (fr)
AU (1) AU2002366604A1 (fr)
BR (1) BR0214842A (fr)
CA (1) CA2469592C (fr)
CO (1) CO5590909A2 (fr)
HR (1) HRP20040534A2 (fr)
HU (1) HUP0402675A2 (fr)
IL (1) IL162325A0 (fr)
IS (1) IS7305A (fr)
MX (1) MXPA04005623A (fr)
NO (1) NO20042916L (fr)
NZ (1) NZ533413A (fr)
PE (1) PE20030763A1 (fr)
PL (1) PL370664A1 (fr)
RU (1) RU2284315C2 (fr)
TW (1) TWI252757B (fr)
UY (1) UY27577A1 (fr)
WO (1) WO2003049690A2 (fr)
ZA (1) ZA200404628B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169932B2 (en) 2001-06-11 2007-01-30 Pfizer Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis
US7094909B2 (en) 2001-06-11 2006-08-22 Agouron Pharmaceuticals, Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
HN2002000136A (es) 2001-06-11 2003-07-31 Basf Ag Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
PA8586801A1 (es) 2002-10-31 2005-02-04 Pfizer Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
BRPI0407052A (pt) 2003-01-27 2006-01-17 Pfizer Inibidores da hiv-integrase, composições farmacêuticas, e métodos para sua utilização
US6890942B2 (en) * 2003-05-16 2005-05-10 Bristol-Myers Squibb Company Acyl sulfonamides as inhibitors of HIV integrase
US20050215544A1 (en) * 2004-03-24 2005-09-29 Pin-Fang Lin Methods of treating HIV infection
US7776863B2 (en) * 2004-03-24 2010-08-17 Bristol-Myers Squibb Company Methods of treating HIV infection
EP1756103A2 (fr) 2004-04-26 2007-02-28 Pfizer, Inc. Dérivés de pyrrolopyridine et leur utilisation comme inhibiteurs de l'integrase du vih
CA2563761C (fr) 2004-04-26 2009-12-29 Pfizer Inc. Inhibiteurs de l'enzyme integrase du vih
US7507838B2 (en) * 2004-09-01 2009-03-24 Bristol-Myers Squibb Company Process for the preparation of Z-5-carboxymethylene-1,3-dioxolan-4-ones
US20060058286A1 (en) * 2004-09-16 2006-03-16 Mark Krystal Methods of treating HIV infection
WO2007086584A1 (fr) * 2006-01-30 2007-08-02 Meiji Seika Kaisha, Ltd. NOUVEL INHIBITEUR DE FabK ET DE FabI/K
WO2008004100A2 (fr) 2006-07-05 2008-01-10 Pfizer Products Inc. Composés thérapeutiques
CA2744509C (fr) * 2008-12-05 2013-10-22 Syngenta Participations Ag Nouveaux pyrazole-4-n-alcoxycarboxamides utilises comme microbiocides
WO2011076765A1 (fr) 2009-12-23 2011-06-30 Katholieke Universiteit Leuven Nouveaux composés antiviraux
US8283366B2 (en) 2010-01-22 2012-10-09 Ambrilia Biopharma, Inc. Derivatives of pyridoxine for inhibiting HIV integrase
WO2012065963A2 (fr) 2010-11-15 2012-05-24 Katholieke Universiteit Leuven Nouveaux composés antiviraux
EP2640729B1 (fr) 2010-11-15 2016-12-21 VIIV Healthcare UK Limited Inhibiteurs de la réplication du vih
IN2014DN09934A (fr) * 2012-04-26 2015-08-14 Bayer Cropscience Ag

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000000458A1 (fr) * 1998-06-26 2000-01-06 Daiichi Pharmaceutical Co., Ltd. Derives de propionyle substitues et leurs intermediaires

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000000458A1 (fr) * 1998-06-26 2000-01-06 Daiichi Pharmaceutical Co., Ltd. Derives de propionyle substitues et leurs intermediaires

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] USUI H. ET AL.: "Preparation of tartaric acid derivatives as squalens synthase inhibitors", XP002964974, accession no. STN Database accession no. 132:78549 *

Also Published As

Publication number Publication date
MXPA04005623A (es) 2004-12-06
PL370664A1 (en) 2005-05-30
US6777440B2 (en) 2004-08-17
TWI252757B (en) 2006-04-11
PE20030763A1 (es) 2003-09-13
TW200301105A (en) 2003-07-01
KR20040065251A (ko) 2004-07-21
HUP0402675A2 (hu) 2005-03-29
CO5590909A2 (es) 2005-12-30
RU2284315C2 (ru) 2006-09-27
IS7305A (is) 2004-06-10
UY27577A1 (es) 2003-07-31
AR037770A1 (es) 2004-12-01
NZ533413A (en) 2006-09-29
CA2469592A1 (fr) 2003-06-19
NO20042916L (no) 2004-09-10
RU2004119963A (ru) 2006-01-10
IL162325A0 (en) 2005-11-20
HRP20040534A2 (en) 2005-04-30
WO2003049690A2 (fr) 2003-06-19
EP1467695A2 (fr) 2004-10-20
CN1617849A (zh) 2005-05-18
BR0214842A (pt) 2005-01-11
CA2469592C (fr) 2005-08-23
US20030176495A1 (en) 2003-09-18
AU2002366604A1 (en) 2003-06-23
JP2005515206A (ja) 2005-05-26
ZA200404628B (en) 2005-09-01

Similar Documents

Publication Publication Date Title
WO2003049690A3 (fr) Inhibiteurs de l'integrase du vih
WO2003082205A3 (fr) Composes et procedes
WO2004096128A3 (fr) Inhibiteurs de l'integrase du vih
WO2004004657A3 (fr) Inhibiteurs de l'integrase du vih
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
WO2002024632A3 (fr) Composants chimiques
WO2005046589A3 (fr) Sels de composes de quinolinone acceptables d'un point de vue pharmaceutique et presentant des proprietes pharmaceutiques ameliorees
WO2001019828A3 (fr) Inhibiteurs de kinase utilises comme agents therapeutiques
DZ3312A1 (fr) Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
WO2004096134A3 (fr) 1,4-diazepines substituees et leurs utilisations
WO2001064645A3 (fr) Derives de quinoline utilises comme antagonistes alpha2
WO2001098248A3 (fr) Inhibiteurs d'integrase du vih
WO2003053971A8 (fr) Antiviraux a base de pyridoquinoxaline
WO1992019211A3 (fr) Imidazobenzoquinones et composition contenant ces dernieres permettant de prevenir ou de traiter l'hypertension ou l'insuffisance cardiaque
WO2003082192A3 (fr) Composes et procedes
CA2437785A1 (fr) Derives de pyrazinone destines a inhiber le vih
WO2001081316A3 (fr) Inhibiteurs de phenyle farnesyltransferase substitues
WO2004111008A3 (fr) Utilisation d'un compose de formule i pour la preparation d'une composition pharmaceutique
DE60114640D1 (en) Antithrombosemittel
WO2009082124A3 (fr) Composition pharmaceutique pour le traitement et la prévention du glaucome
CA2326076A1 (fr) Nouveaux macrolides
WO2002026732A1 (fr) Derive de benzodiazepine
MY129094A (en) Condensed polycyclic compounds
WO2004048381A3 (fr) Nouveaux composes de pyrazoloazepine utilises en tant qu'agents pharmaceutiques

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1200400625

Country of ref document: VN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1518/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 162325

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 533413

Country of ref document: NZ

Ref document number: 04054295

Country of ref document: CO

Ref document number: P-508/04

Country of ref document: YU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/005623

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2469592

Country of ref document: CA

Ref document number: 2002366604

Country of ref document: AU

Ref document number: P20040534A

Country of ref document: HR

Ref document number: 1020047009018

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003550741

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002804741

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 5665

Country of ref document: GE

Ref document number: 8288

Country of ref document: GE

WWE Wipo information: entry into national phase

Ref document number: 20028279700

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1-2004-500859

Country of ref document: PH

WWP Wipo information: published in national office

Ref document number: 2002804741

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002804741

Country of ref document: EP